A subject-level analysis of 91 placebo-controlled trials covering nearly 108,000 participants found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonists compared with placebo. The findings address safety concerns raised around psychiatric events in large real-world conversations. The analysis looked across the trial dataset at the participant level, providing a more granular assessment than pooled event rates. The company-facing takeaway is that the signal investigators sought to quantify did not emerge in these placebo-controlled settings. The report does not argue against monitoring, but it directly counters claims of higher suicide-related risk attributable to GLP-1 therapy within the examined trial programs.